The MarketWatch News Department was not involved in the creation of this content. Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab ...
- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism - Deal worth up to $415m including ...
U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...
Alchemab using unique approach to explore adaptive immunity - identifying naturally protective antibodies in ‘resilient patients’ to specific diseases Innovate UK Grant to support the finding of a ...
Proof-of-concept immuno-oncology collaboration with AstraZeneca to build understanding of prostate cancer Alchemab’s advanced analytics to be used to analyse patient immune responses, identify natural ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback